Trans NCI Initiatives Role of imaging as an enabling technology

Similar documents
QIN: Overview of Scientific Challenges

NCI Research Networks Model for Collaboration with Bioelectronics Round Table

Informatics Tools for Optimized Imaging Biomarkers for Cancer Research & Discovery

TOTAL CANCER CARE: CREATING PARTNERSHIPS TO ADDRESS PATIENT NEEDS

Comparative Oncology Program

QIBA RIC Collaboration

REQUEST FOR APPLICATIONS. MMRF Immunotherapy Networks of Excellence

Precision Medicine Catapult

NINDS/HEAL Biomarker Programs New Biomarker Initiatives at NIH: Neurological Disorders and Pain

Overview of NIBIB Research Areas and Funding Opportunities. There are 27 Institutes and Centers (ICs) at the NIH NIBIB

Topic: Genome-Environment Interactions in Inflammatory Skin Disease

Specialty Lab Services. Deep science at scale

PET/CT imaging for response monitoring in multicenter studies: An update and future challenges

The Power to Cure: Therapeutic Innovation in Academia

Economic Impact. IWGSC March 12, Jim Vaught, Ph.D. Jim Vaught, Ph.D. Deputy Director. ESBB Marseille November 2011

Precision Medicine. Presented by:

RSNA RCA22 Quantitative Imaging: Structured Reporting in 3D Slicer and beyond

Enabling Precision Medicine: The Role of Genetics in Clinical Drug Development A Workshop

UC Davis Collaborative for Diagnostic Innovation. Lydia P. Howell MD Professor and Chair, Pathology & Laboratory Medicine

UC Davis Collaborative for Diagnostic Innovation. Lydia P. Howell MD Professor and Chair, Pathology & Laboratory Medicine

AAPM Scientific Meeting Imaging Symposium. State of the Art in Quantitative Imaging CT, PET and MRI. Which Imaging Modality is the Most Quantitative

Konica Minolta to Acquire Invicro (US)

CQIE MRI PROCEDURES. American College of Radiology Clinical Research Center. Centers for Quantitative Imaging Excellence LEARNING MODULE

QPS Neuropharmacology Overview

Phase 1 Clinical Studies First-In-Human (FIH) <Chapter 31> Pharmacologically-Guided Dose Escalation

Principles of translational medicine: imaging, biomarker imaging, theranostics

In Vitro Companion Diagnostic Devices

Imaging Researcher s Workshop Annotation and Imaging Markup. Introduction

Vision, aims and strategies. Department of Immunology, Genetics and Pathology Uppsala University

CIP Branch: Research Mission Open Science: Validation Strategies

From Analysis Method to Quantitative Imaging Biomarker

ORACLE OTTAWA REGION FOR ADVANCED CARDIOVASCULAR RESEARCH EXCELLENCE STRATEGIC DIRECTIONS

A unique Collaborative Model for the Discovery of New Therapeutic Approaches

DNA. Clinical Trials. Research RNA. Custom. Reports CLIA CAP GCP. Tumor Genomic Profiling Services for Clinical Trials

Summary. Science - Communication - Innovation Management - Clinical Investigation

REIMAGINING DRUG DEVELOPMENT:

THE WHITE HOUSE Office of the Vice President

Translational Medicine From Discovery to Health

Request for Projects for Wake Forest Brain Tumor SPORE Application

Supplementary Materials for

Jeffrey T. Yap, Ph.D. Dana-Farber Cancer Institute Brigham & Women s Hospital Harvard Medical School

Adis Journals and Newsletters The premier collection of drug-focused medical journals

Our website:

The SWOG ITSC Pilot Awards: Request for Application 2018 Announcement


SPECTArare as an innovative model of combining clinical research and care in an ERN. Denis Lacombe, MD, MSc EORTC, Director General Brussels, Belgium

Partnering in Oncology Sharing a Vision to Help Prolong and Improve Patients Lives. Oncology Therapeutic Area Janssen Research & Development, LLC

Robert Jeraj, Scott Perlman. Wisconsin Oncology Network of Imaging excellence (WONIX) University of Wisconsin Carbone Cancer Center, Madison, WI

Innovative Medicines Initiative

Overview of the Luxembourg biomedical and health research ecosystem FNR FRANK GLOD LUXCOR HEALTH EVENT MONDAY 19 JUNE 2017

Why Culture Matters in Cancer Research

Personalised Medicine Regulatory Issues

M a x i m i z in g Value from NGS Analytics in t h e E n terprise

8/2/2017. Key attributes of scientific excellence: rigor, innovation, and relevance. Medical Physics 3.0. Key Attributes of Scientific Excellence

Clinical Trial Design, Approval Process and Trial Conduct

SMEs in IMI2 Calls for Proposals

Chairman Cole, Ranking Member DeLauro and distinguished members of the

Personalized. Health in Canada

BOARD PAPER - NHS ENGLAND. Purpose of Paper: To inform the Board of the development of an NHS England Personalised Medicine Strategy.

Forthcoming Calls for Proposals (10/11) Barcelona 28 June 2013

Per Morten Sandset Japan-UiO cooperation within health and care research status and opportunities

Research Opportunities at NIGMS. Stephen Marcus, Ph.D.

Data representation for clinical data and metadata

Evaluation and Regulation of Biomarkers A Public Health Perspective

PATIENT STRATIFICATION. 15 year A N N I V E R S A R Y. The Life Sciences Knowledge Management Company

A whole-system approach to delivering personalised medicine and health in Leeds. Mike Messenger

A biomarker-based adaptive two-stage randomizedphase II study design

BUILDING AN IDEAL WORLD FOR IMPROVING PATIENT OUTCOMES IN ONCOLOGY. Myeloma Canada s experience

Corporate Presentation. February 2, 2018

What is Precision Medicine?

Genomic Medicine in France

Quantitative Imaging Biomarker DCE - MRI

Horizon 2020 Review of Work Programme Focus on topics including Clinical Trials/Studies

TRANSFORMING CLINICAL RESEARCH FOR FASTER ACCESS TO INNOVATIVE MEDICINES. Establishing the Value of EHR4CR for Pharmaceutical Industry

Novel nuclear medicine to advance patient care

The EORTC Molecular Screening programme SPECTA

Le banche dei tessuti

NIHR Cambridge Clinical Research Facility

Introducing a Highly Integrated Approach to Translational Research: Biomarker Data Management, Data Integration, and Collaboration

Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development

Antibody Discovery at Evotec

Technical Guidance on Development of In Vitro Companion Diagnostics and Corresponding Therapeutic Products

Centre for Personalised Medicine in Tübingen - developing tailor-made treatments for patients

Complex Adaptive Systems Forum: Transformative CAS Initiatives in Biomedicine

Precision in Quantitative Imaging: Trial Development and Quality Assurance

A bold vision for 2025

Rare diseases in the 7th EU Framework Programme for Research and Technological Development

Recent Trends in Companion Diagnostic Test Development Partnerships

A New Era of Clinical Diagnostics: How the Business Model is Changing.

The National Institutes of Health ICs: mission and funding strategies

IMI: Accelerated Drug Portal. Julia Brosnan on behalf of Innovative Medicines Initiative

LesionTracker Open Source Oncology Web Viewer Funded through NCI ITCR U24 Program

Government Bioscience Grant (GBG) Report October 2016 BROAD AGENCY ANNOUNCEMENTS CANCER

Our Research Strategy

Total genomic solutions for biobanks. Maximizing the value of your specimens.

2017 Precision Medicine Study

International bio-medical imaging based R&D and support imaging CRO and ARO service. LISIT, Co.,Ltd.

Challenges in developing Biomarker Assays for patient selection and Companion Diagnostic (CDx) Assays in early and late stage of drug development

Deep Learned and Practical

6 Critical Factors for Achieving Success on the Accelerated Approval Pathway for Oncology Drugs

Transcription:

Oncology Co-Clinical Research Resources (Us) to Develop Best Practices for Quantitative (QI) in Mouse Models A Trans-NCI Initiative Larry Clarke, PhD, Branch Chief, CIP DCTD AAPM Meeting July th 0 Trans NCI Initiatives Role of imaging as an enabling technology Biology (DCB) Prevention (DCP) Diagnosis (CBIIT) Program Genomics (DCB) Therapy must become relevant to other research domains Precision medicine requires: Better animal models & novel research methods Collins FS, and Varmus H, A new initiative on precision medicine, NEJM, 9:79 (0) http://www.nih.gov/precisionmedicine/ Preclinical Study Prospective Parallel (Co-clinic) Retrospective Clinical Study

Challenges in co-clinical trial imaging Diverse range of preclinical imaging platforms Not optimized for multi-platform-site investigations Lack of resources to promote best practices for QI Preclinical QI methods need to be optimized to improve correlation studies for the co-clinical trial Lunardi A, et al. Trends in Molecular Medicine, : (0). New U Initiative: PA--6 Clinical Trial Goals Oncology Co-Clinical Research Resources to Encourage Consensus on Quantitative Methods and Precision medicine (U). Therapeutic goal: Prediction, staging and/or measurement of response to cancer therapies Screenings goal : Early detection or cancer risk stratification for lethal cancers verses non-lethal disease Quantitative imaging Mouse models* Co-clinical trials Purpose of PAR Support multi-disciplinary teams Mouse modelers, quantitative imaging, informatics-resources Propose co-clinical trials using best practices Validated and credentialed mouse and human-in-mouse models Propose best practices for data collection and analysis Permit quantitative correlation studies, and other commercial biomarker assays Propose means to archive data, methods and software tools NCI existing resources (TCIA) Share methods and results in the OMF Hub Provide a framework to exercise software grand challenges.

Coordination with other NCI PARs Oncology Models Forum (Us) Academic Industry Partnership (R0s) Co-clinical Research Resource (Us) Quantitative Network (U0s) ITCR (U0s, Us) Leverage research resources and methods Modeled after the QIN U0 s PAR--6: Quantitative for Evaluation of Response to Therapies (U0): Develop innovative methods for data collection and analysis Collect image data from ongoing phase I-III clinical trials to generate a clinical research technical resource Explore a means to develop a consensus on quantitative imaging methods for validating clinic imaging tools Open Science Phase I-III Trials Technical Sites Data Collection & Variance Studies Data Analysis & Tool Validation Clinical Trial Design & Data Sharing QIN Working Groups Quantitative Tools Clinics QIN is a test bed for ITCR and AIP Activities Technology for Research ITCR Complementary U Awards Open Source Questions? QIN Teams zhanghui@mail.nih.gov 6 Complementary R0Awards Translational Research Academic/Industrial Partnership s AIP (ROI s)

NCI: The Archive (TCIA) Being modified to host DICOM for pre-clinical data Linked to The Genome Atlas-(TCGA) TCIA- Genomic Correlation TCIA: National CT Lung Screening Trial Data (NLST) Quantitative Network Data (QIN) Requirements: Co-clinical Trial Prospective co-clinical therapy trial State of the art quantitative imaging methods Commercially supported imaging platforms Exception: risk or prevention studies Same Class of imaging platform (PET-CT, MRI) Trial costs not covered; additional QI methods are Data size and quality should be sufficient to provide: Robust statistical comparison of QI methods Retrospective co-clinical trial State of the art QI methods at the time of the trial, Methods must be well documented Requirements: Co-clinical Trial The therapeutic goal: The primacy or secondary dug to be tested should be known to have a response in tumors that match histologically or gnomically to the mouse model For the prevention goal: The form of intervention shown be known to be effective with the context of early cancer detection or prevention For the mouse model goal: Should be available, validated and credentialed using published recommended best practices Animal care meet IACUC best practices: Longitudinal studies

Requirements: Co-clinical Trial Populate an internet accessible research resource: Collected co-clinical trial data, detailed methods, related software tools (metrology tools, and results of the correlation studies) The use of NCI funded research resources is highly recommended as being implemented by the trans-nci Oncology Models Forum: The Archive (TCIA) The NCI NCIP HUB Network wide consensus approaches will be explored when the U network is established, similar to the QIN network Demonstrate the resource functionality Software grand challenges, similar to the QIN network Compare the performance of current and improved tools Suggestions for planned applications Organize multiple disciplinary teams experienced in: Mouse model research Human investigations platforms QI methods, Clinical decision support tools as required to create the research resource Before the full development of the application Have all key members read the full PAR Contact NCI to set up a TCON to ensure you are being responsive to the full requirements of this complex PAR